Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 16, 2022; 10(8): 2491-2496
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2491
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2491
Severe tinnitus and migraine headache in a 37-year-old woman treated with trastuzumab for breast cancer: A case report
Yong-Zhi Liu, Hai Jiang, Yong-Hua Zhao, Qi Zhang, Shi-Chao Hao, Li-Ping Bao, Wei Wu, Zhao-Bo Jia, Hui-Chuan Jiang, Department of Breast Surgery, General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group, Benxi 117000, Liaoning Province, China
Author contributions: Liu YZ made contribution to treating the patient, collecting data and writing the article; Jiang H, Zhao YH, Zhang Q, Hao SC, Bao LP, Wu W, Jia ZB, Jiang HC made contribution to treating the patient.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there is no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Zhi Liu, PhD, Chief Doctor, Department of Breast Surgery, General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group, No. 29 Benxi Renmin Road, Benxi 117000, Liaoning Province, China. jackdemi@163.com
Received: July 13, 2021
Peer-review started: July 13, 2021
First decision: September 28, 2021
Revised: October 9, 2021
Accepted: January 29, 2022
Article in press: January 29, 2022
Published online: March 16, 2022
Processing time: 240 Days and 20.3 Hours
Peer-review started: July 13, 2021
First decision: September 28, 2021
Revised: October 9, 2021
Accepted: January 29, 2022
Article in press: January 29, 2022
Published online: March 16, 2022
Processing time: 240 Days and 20.3 Hours
Core Tip
Core Tip: Trastuzumab is an important treatment for human epidermal growth factor receptor 2-positive breast cancer and is generally well-tolerated, although both acute and subacute adverse events have been reported. Here, we report a rare case of severe tinnitus and migraine induced by trastuzumab used for adjuvant therapy which may help guide future clinical treatment.